Interview with Peter Schmidt, President, ProGenerika
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
Address: Unter den Linden 32-34. D-10117 Berlin,Germany
Tel: +4930 – 81 61 60 9 – 0
Web: http://www.progenerika.de/
ProGenerika is the industry association of generic manufacturers in Germany. It represents the interests of 16 large, medium and small enterprises, focusing on the development and production of generic medicines. The members of ProGenerika cover more than three-quarters of the entire German generics market.
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
The latest news from German pharma, including looming drug pricing reform, Boehringer Ingelheim’s EUR 640 million acquisition of a Kyowa Kirin autoimmune drug, and BioNTech’s updated revenue guidance. Also covered…
Rainer Westermann of European life science venture capital lobby group, the Life Sciences Acceleration Alliance, lays out a policy roadmap for how innovative European pharma can continue to grow and…
Once a little-known mRNA pioneer, BioNTech became a household name with its COVID-19 vaccine developed alongside Pfizer. But the German biotech is now pursuing an even bigger transformation — and…
A summary of some of the top stories coming out of Germany’s biopharma industry, including Bayer’s EMA win for its Eylea eye therapy; the oncology deal Merck KGaA has cut…
After February’s snap election that brought Friedrich Merz to power, a coalition between his conservative CDU/CSU bloc and the centre-left SPD has outlined an agreement this month that will serve…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. looks out over the choppy waters for life sciences venture capitalists in Europe over 2025. Three key initiatives stand to…
European pharma is at a turning point, with rising cost pressures, regulatory shifts, and supply chain vulnerabilities reshaping the industry. As the new president of Medicines for Europe, STADA’s Stephan…
A roundup of the biggest stories coming out of Germany’s pharma industry, including Bayer’s biggest share price drop in 20 years; Fresenius Kabi’s biosimilar deal with SamChunDang Pharm; Halozyme Therapeutics’…
The latest news from German pharma, including why Merck KGaA is looking to life science M&A; positive outlooks for Bayer and STADA; BioNTech’s move into the AI lab assistant space…
A roundup of some of the biggest stories coming out of German pharma, including Merck’s better-than-expected Q1 earnings; Stada’s possible return to the stock market; CDMO Vetter’s expanded capacity in…
Oskar Möbert, vice president of Veeva OpenData, discusses how standardizing customer reference data and systems organization-wide can help biopharmas scale globally and become more agile in their business. Data…
The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion…
See our Cookie Privacy Policy Here
